GLUCAGON ANTAGONISTS

Provided herein are compounds of Formula I, where the variables are as defined herein, and pharmaceutically acceptable salts, solvates or prodrugs thereof having an optical purity of at least 95% of the R enantiomer which have glucagon receptor antagonist or inverse agonist activity. Further, provid...

Full description

Saved in:
Bibliographic Details
Main Authors HECKER, Scott J, GOMEZ-GALENO, Jorge E, REDDY, Mali Venkat, SUN, Zhili, DANG, Qun, NGUYEN, Thanh Huu, LI, Haiqing, LEMUS, Robert Huerta, GROTE, Matthew P
Format Patent
LanguageEnglish
Published 31.10.2019
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided herein are compounds of Formula I, where the variables are as defined herein, and pharmaceutically acceptable salts, solvates or prodrugs thereof having an optical purity of at least 95% of the R enantiomer which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well the the same for use in methods of treating, preventing or ameliorating a condition, disorder or disease for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Formula I
Bibliography:Application Number: US201916289241